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Abstract
Introduction: Acne, a chronic inflammatory disorder of pilosebaceous unit, is char-
acterized by comedones, pustules, papules, nodules, cysts, and scars. It affects nearly 
85% of adolescents. High sebaceous gland secretion, follicular hyperproliferation, high 
androgen effects, propionibacterium acnes colonization, and inflammation are major 
pathogenic factors. Systemic disease or syndromes that are associated with acne are less 
commonly defined. Therefore, these syndromes may not be usually recognized easily.
Research methods: Acne-associated syndromes prove the nature of these diseases and 
are indicative of pathogenesis of acne. Polycystic ovary (PCOS), synovitis-acne-pustu-
losis-hyperostosis-osteitis (SAPHO), hyperandrogenism-insulin resistance-acanthosis 
nigricans (HAIR-AN), pyogenic arthritis-pyoderma gangrenosum-acne (PAPA), pyo-
derma gangrenosum-acne vulgaris-hidradenitis suppurativa-ankylosing spondylitis 
(PASS), pyoderma gangrenosum-acne conglobate-hidradenitis suppurativa (PASH), 
seborrhea-acne-hirsutism-androgenic alopecia (SAHA), and Apert syndromes are well-
known acne-associated syndromes. Endocrine disorders (insulin resistance, obesity, 
hyperandrogenism, etc.) can be commonly seen in these syndromes, and there are too 
many unknown factors that must be investigated in the formation of these syndromes.
Conclusion—key results: If we are aware of the component of these syndromes, we will rec-
ognize those easily during dermatological examination. Knowledge of clinical manifestations 
and molecular mechanisms of these syndromes will help us to understand acne pathogenesis. 
When acne pathogenesis is explained clearly, new treatment modalities will be developed.
Keywords: acne, syndrome, PCOS, HAIRAN, PAPA, PASH, Apert, SAPHO, SAHA, 
acne-associated syndromes
1. Introduction
Acne vulgaris is a common chronic inflammatory disease of the pilosebaceous unit. Acne is 
typically thought as an adolescent disease but it is also seen in adulthood anymore [1].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Although there are lots of studies about the pathogenesis of acne, all pathogenetic factors 
are not known very well. Four main pathways are described in acne pathogenesis: increased 
sebum production, abnormal keratinization, Propionibacterium acnes colonization, and inflam-
mation [2]. Acne is a multifactorial disease and sometimes associated with systemic disorders. 
Acne may be a potential skin marker of internal disease or a component of syndromes such as 
PCOS, HAIR-AN, PAPA, PASH, SAPHO, SAHA, and Apert. To know about the pathogenesis 
of those will help us to understand the acne pathogenesis [3, 4].
Herein, we aim to mention about acne-associated syndromes and their clinical and pathoge-
netic features.
2. Polycystic ovary syndrome (PCOS)
Polycystic ovary syndrome (PCOS) is an ovarian disease characterized by hyperandrogenism, 
chronic anovulation, and polycystic ovaries. It is one of the most common endocrinopathy 
that affects 4–12% of women of reproductive age [5].
Its etiology is unknown, but it was first described by Drs Irving Stein and Michael Leventhal 
in 1935. They discovered polycystic ovaries in seven patients who had anovulation during 
surgery and described this disorder as the name of Stein-Leventhal syndrome [6]. Later diag-
nostic criteria were developed.
The National Institutes of Health (NIH), the Rotterdam, and the Androgen Excess Society 
Criteria are used for the diagnosis of PCOS [7, 8]. Nowadays, NIH criteria are the preferred 
diagnostic criteria in adolescents [9].
NIH criteria are the presence of oligoovulation or anovulation and biochemical or clinical 
signs of hyperandrogenism [9]. Before the diagnosis with using these criteria, some condi-
tions must be excluded that result in anovulation and hyperandrogenism, such as congenital 
adrenal hyperplasia, Cushing’s syndrome, and androgen secreting tumors [9]. Thyroid dis-
ease, hyperprolactinemia must also be excluded.
Although pathogenesis of PCOS is not understood very well, it is thought that hormonal 
pathways contribute to this process. The pulse frequency of gonadotropin-releasing hormone 
(GnRH) increases in PCOS and stimulates to the anterior pituitary gland to secrete luteinizing 
hormone (LH) more than follicle-stimulating hormone (FSH), resulting in an increased ratio 
of LH to FSH. The increase in LH relative to FSH stimulates the ovarian theca cells to syn-
thesize androstenedione. Consequently, the net ovarian androgen production increases [10]. 
Insulin has also a role in the pathogenesis of PCOS by stimulating the ovarian theca cell to 
secrete androgens as LH and also inhibits hepatic production of sex hormone binding globu-
lin (SHBG). As a result, free and total androgen level increases.
Obesity is another component of this syndrome and contributes pathogenesis via insulin 
resistance [10].
Insulin resistance and hyperandrogenism are responsible for the cutaneous involvement of 
PCOS. Insulin resistance causes acanthosis nigricans (AN), and hyperandrogenism leads 
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to hirsutism, acne, oily skin, seborrhea, and hair loss (androgenic alopecia). It is estimated 
that 72–82% of women with PCOS have cutaneous signs [11]. PCOS has also multisystemic 
effects and is associated with lots of diseases including infertility, endometrial cancer, obesity, 
depression, sleep-disordered breathing/obstructive sleep apnea (OSA), nonalcoholic fatty 
liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH), type 2 diabetes mellitus 
(T2DM), and cardiovascular diseases [9]. Patients with PCOS are usually first seen by a der-
matologist. Because of the above comorbidities, dermatologists should know the diagnosis 
and clinical findings of PCOS very well.
Cutaneous findings in women with PCOS are related to abnormalities of the pilosebaceous 
unit. Increased androgen levels activate abnormal development of the pilosebaceous unit, and 
hirsutism, acne or androgenic alopecia. Androgenic alopecia is luckily rare among women 
with PCOS because of its complex etiology. Acanthosis nigricans (AN) and skin tags are the 
other skin disorders in PCOS [12].
Although acne, hirsutism, and AN were the most common skin manifestations, hirsutism 
and AN were the most sensitive for PCOS diagnosis [13]. In previous reports, the range of 
acne prevalence in PCOS is 15–95%. While hirsutism affects 5–15% of women in the general 
population, previous reports showed hirsutism prevalence between 8.1 and 77.5% in women 
with PCOS. In patients with PCOS, hirsutism is also a sign of metabolic abnormalities [13].
AN is also associated with substantial metabolic dysfunction (increased insulin resistance, 
glucose intolerance, body mass index, and dyslipidemia).
Therefore, the presence of AN and hirsutism should warn us regarding a patient’s potential 
metabolic risk factors. A broad range in the prevalence of AN among women with PCOS 
(2.5% in the United Kingdom, 39 5.2% in Turkey, 16 and 17.2% in China) were observed [13].
Although patients with PCOS frequently refer to dermatologists with cutaneous concerns, it 
is important to educate them about the metabolic and fertility-related implications of PCOS.
Hormonal therapy (combination estrogen and progesterone oral contraceptives, antian-
drogens: spironolactone, cyproterone acetate, drospirenone, flutamide, and inhibition of 
peripheral androgen conversion: finasteride), insulin-sensitizing agents (metformin, thia-
zolidinediones), and nonhormonal therapy (standard acne, hirsutism, androgenetic alopecia 
therapy) are treatment options [14].
Pharmacologic treatment is not every time necessary for all patients with PCOS. Mild forms 
of hirsutism, acne, and androgenetic alopecia may be controlled with standard nonhormonal 
agents and life style changes (weight loss, diet, exercise, glucose control) [14].
3. Hyperandrogenism-insulin resistance-acanthosis nigricans syndrome 
(HAIR-AN syndrome)
Hyperandrogenism-insulin resistance-acanthosis nigricans syndrome (HAIR-AN syndrome) 
is a subphenotype of polycystic ovary syndrome. It is clinically characterized by acne, obe-
sity, hirsutism, and acanthosis nigricans. It usually manifests in early adolescence. Although 
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etiology is not known very well, genetic, environmental factors, and obesity are estimated to 
cause HAIR-AN syndrome. The primary abnormality in patients with HAIR-AN syndrome is 
thought to be severe insulin resistance. In those patients, insulin levels increase and stimulate 
the overproduction of androgens in the ovaries [15].
Patients may also present with amenorrhea and signs of virilization. Although adrenal function 
is normal, the levels of insulin, testosterone, and androstenedione may be high. Adolescents 
with HAIR-AN syndrome usually have normal levels of luteinizing hormone (LH) and folli-
cle-stimulating hormone (FSH) but the ratio of LH to FHS is usually more than one [16].
Clinical findings are related to insulin resistance and hyperandrogenism so patients first refer 
to dermatologist, endocrinologist, or gynecologist with hyperandrogenism signs (hirsutism, 
androgenic alopecia, male body habitus acne, menstrual dysfunction, increased libido, cli-
torimegaly) or insulin resistance signs (polydipsia, polyuria (often subclinical), acanthosis 
nigricans, skin tags, and obesity [17] (Figure 1).
Polycystic ovary syndrome (71–86%), congenital hyperplasia of the adrenal (3–10%), adrenal 
and ovarian tumors (0.3%), and idiopathic hirsutism (10%) are, respectively, the most com-
mon reasons of hyperandrogenism. Except those, HAIR-AN syndrome should also keep in 
mind as a reason of hyperandrogenism that is seen in almost 5% of females with hyperan-
drogenism [18].
Figure 1. Acanthosis nigricans, from Nahide Onsun’s photos.
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For HAIR-AN syndrome diagnosis and follow-up, in addition to history and physical exami-
nation, a complete blood cell count, thyroid screen, serum prolactin, glucose and insulin mea-
surements, serum electrolyte, and lipid panel should be evaluated [17] because Cushing’s 
syndrome, Hashimoto’s thyroiditis, Grave’s disease, and congenital adrenal hyperplasia 
may accompanied with HAIR-AN syndrome [4]. To investigate the origin of hyperandrogen-
ism, total testosterone, levels of 17-hydroxyprogesterone, dehydroepiandrosterone sulfate 
(DHEAS), levels of luteinizing and follicle-stimulating hormones, and morning cortisol after 
a low dose of dexamethasone should be analyzed [17].
High level of DHEAS should warn us about the possibility of an androgen-producing tumor 
of the adrenal gland. Increased 17-hydroxyprogesterone is usually seen in congenital adrenal 
hyperplasia. Patients with Cushing’s syndrome have elevated levels of circulating androgen, 
and abnormal secretion of cortisol. In those, increased basal levels of cortisol and failure of 
suppression after stimulation with dexamethasone are observed. In polycystic ovarian syn-
drome, LH/FSH ratio is usually >2.5 (may see in normal patients as well). Although there 
is not an underlying virilizing tumor (ovarian or adrenal) in HAIR-AN syndrome, plasma 
testosterone level is high [19].
In the treatment, lifestyle changes like exercise, lower-calorie diet rich in fiber and protein are 
advised to patients. Metformin can also be prescribed. Other choices are estroprogestatif pills 
and antiandrogens [20].
4. SAHA syndrome
SAHA syndrome was first described in 1982, characterized by seborrhea, acne, hirsutism, and 
androgenetic alopecia [21]. The SAHA syndrome is classified into four types: idiopathic, ovar-
ian, adrenal, and hyperprolactinemic [21], and it can be associated with polycystic ovaries, 
cystic mastitis, obesity, insulin resistance, and infertility [4, 21].
In the pathogenesis of SAHA, increased androgen synthesis in adrenals and ovaries, dis-
turbed peripheral metabolism of androgens, or induction of metabolism and activation of 
androgens in the skin may play important role [4].
Approximately 20% of the patients have all four major signs of SAHA syndrome. Seborrhoea 
is observed in all of patients, androgenetic alopecia is seen in 21% of the patients, and acne in 
10% and hirsutism in 6% of the patients [4].
The management of disorder resembles HAIR-AN and PCOS [22].
5. APERT syndrome
Apert syndrome is a rare congenital type I acrocephalosyndactyly syndrome (acrocephalosyn-
dactyly type I). It was first described in 1906 by the French physician Eugène Apert, characterized 
by the premature fusion of the craniofacial sutures and syndactyly of the hands and feet [23].
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The syndrome is inherited in an autosomal dominant fashion, a rare congenital disease. It is 
caused by a genetic mutation in the FGFR2 gene, and approximately 98% of all patients have 
specific missense mutations of FGFR2 [24].
FGFR2 is responsible for the development of embryonic skeleton, epithelial structures, and 
connective tissue [25]. Craniofacial deformities, hypertelorism, dental and palatal abnor-
malities, proptosis of the eyes, different skeletal deformities, hydrocephalus, abnormal 
brain development, mental retardation, blindness, cardiovascular, urogenital, gastrointes-
tinal, respiratory, and skin abnormalities can be seen in patients with Apert syndrome [25].
Dermatologic associations of Apert syndrome was not known when first described in 1906 
[26]. In 1970, Solomon first reported the dermatologic manifestation of this disorder, which is 
severe acneiform lesions [27]. The other skin manifestations are hyperhidrosis, hypopigmen-
tation, and hyperkeratosis of plantar surfaces [27].
In this syndrome, the pathogenesis of acne is not understood very well but increased fibro-
blast growth factor receptor-2 (FGFR2)-signaling is suspected to be of pathophysiological 
importance in acne vulgaris because it was reported that in skin cultures, keratinocyte-derived 
interleukin-1α stimulated fibroblasts to secrete FGF7 which stimulated FGFR2b-mediated 
keratinocyte proliferation [28]. In acne pathogenesis, increased levels of interleukin-1α (IL-
1α) are seen in comedones, and an important pro-inflammatory cytokine stimulates kerati-
nocyte proliferation, hyperkeratinization, and decreased desquamation of comedo formation 
[28]. Patients with Apert syndrome usually have oily skin. Moderate to severe acne, occurring 
in childhood or early adolescence, affecting the forearms, which is an unusual site for conven-
tional acne, is often observed [23, 28]. Comedones, papules, pustules, furunculoid cysts, and 
scars as seen in conglobate acne can be seen. It is very difficult to treat, and often unresponsive 
to therapy but good response to oral isotretinoin [23, 26, 28].
Although isotretinoin therapy has good treatment option, it has serious adverse effects such 
as teratogenicity, hepatic dysfunction, elevation of cholesterol and triglyceride levels, visual 
changes, pseudotumor cerebri, musculoskeletal pain, hyperostosis, mucocutaneous dryness, 
and dryness of the eyes. Therefore, the risk/benefit ratio in treatment of acne lesions with 
isotretinoin in children with Apert syndrome should be evaluated well [26].
6. Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) 
syndrome
SAPHO syndrome was first defined in 1987 by Chamot et al. and its characteristic clinical findings 
are synovitis, acne, pustulosis, hyperostosis, and osteitis [29]. The etiology is controversial [30]. 
Although infections (Propionibacterium acnes, Corynebacterium sp.), seronegative spondylo-
arthropathies (psoriasis, sacroiliitis, enthesitis, inflammatory bowel disease, axial involvement), 
genetic factors, and stress were responsible for the pathogenesis, those are only hypothesis [30].
Propionibacterium acnes is estimated to play a pathogenic role in SAPHO syndrome. 
Productions of microbial determinants of P. acnes stimulate innate immune response through 
TLR-2. TLR-2 induces inflammatory cytokines via NF-jB and mitogen-activated protein kinase 
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pathway [31]. Recent reports also showed that SAPHO syndrome had similar features with 
other autoinflammatory disease. IL-1β, TNF-α, and IL-8 were suggested to be important in 
the pathogenesis of SAPHO [32].
Two cohort studies investigated genes PSTPIP2, LPIN2, NOD2, PSTPIP1, and PTPN22, but did 
not show causal mutations. Therefore, SAPHO syndrome is thought as a polygenic disease [33].
SAPHO syndrome is a rare disease so usually misdiagnosed because this syndrome have sim-
ilar clinical features with infectious discitis, seronegative SpA, and psoriatic arthritis (PsA), 
and skin and bone lesions may appear at different times [34].
Standard diagnostic criteria are also controversial such as etiology. The commonly used diag-
nostic criteria of SAPHO syndrome: (i) local bone pain with gradual onset; (ii) multifocal 
lesions, especially in the long, tubular bones and spine; (iii) failure to culture an infectious 
microorganism; (iv) a protracted course for several years with exacerbations and improvement 
with anti-inflammatory drugs; and (v) neutrophilic skin eruptions, mostly palmoplantar pus-
tulosis (PPP), nonpalmoplantar pustulosis, psoriasis vulgaris, or severe acne [30] (Figure 2).
The skin manifestations are those of different neutrophilic dermatoses. PPP is the most com-
mon skin involvement, including pustular psoriasis, representing 50–75% of all dermatologic 
manifestations, psoriasis vulgaris may also be seen among the dermatologic manifestations 
of SAPHO. One fourth of patients have acne conglobata and fulminans with men clearly pre-
dominating [34]. Hidradenitis suppurativa may also be seen.
Figure 2. Pustular psoriasis, from Nahide Onsun’s photos.
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PG, Sweet’s syndrome, and Sneddon-Wilkinson disease are the other rare cutaneous manifes-
tations. IBD especially Crohn’s disease may also be accompanied with SAPHO syndrome [34].
The most of author agree about that SAPHO could be classified within the spectrum of auto-
inflammatory diseases. Therefore, intra-articular or systemic corticosteroids, disease-modify-
ing antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine, cyclosporine, and 
leflunomide are the treatment options but there are no randomized controlled clinical trials 
for the treatment. Doxycycline can also be thought as a treatment option for P. acnes eradi-
cation [33] Infliximab (INFX), an anti-TNF-α monoclonal antibody, has been showed effec-
tive for the treatment SAPHO patients especially unresponsive or refractory to conventional 
drugs. In recent case series, remarkable improvement of bone, joints, and skin inflammatory 
manifestations was observed with Infliximab (INFX) therapy. In resistant SAPHO cases, the 
IL-1 antagonist anakinra can be also tried [35, 36].
7. PAPA syndrome
PAPA syndrome (pyogenic arthritis, pyoderma gangrenosum, and acne) is an autosomal 
dominant, autoinflammatory disorder. PAPA syndrome was first described as a hereditary 
disease in 1997 [37]. There is a PSTPIP1/CD2BP1 mutation on chromosome 15q that causes 
an increased binding affinity to pyrin and induces the assembly of inflammasomes [37]. The 
caspase, a protease, is activated and converts inactive prointerleukin (IL)-1 beta to its active 
isoform IL-1 beta. Overproduction of IL-1 beta induces to release pro-inflammatory cytokines 
and chemokines. Those are responsible for the recruitment and activation of neutrophils, 
leading to a neutrophil-mediated inflammation [38].
PAPA syndrome is usually presents with severe self-limiting pyogenic arthritis in early 
childhood. Pyoderma gangrenosum (Figure 3) and nodular-cystic acne may be seen around 
puberty and adulthood [37]. Pathergy test is positive in PAPA syndrome and clinically appears 
as pustule formation followed by ulceration [34]. There is not a diagnostic test but acute phase 
reactants and white blood cell count may be elevated because of systemic inflammation [34].
Figure 3. Pyoderma gangrenosum, from Nahide Onsun’s photos.
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Arthritis usually gives good response to therapy with corticosteroids. Pyoderma gangreno-
sum is treated with topical or systemic immunosuppressant drugs. In addition, a few reports 
showed that anti-TNF-α and anti-IL-1 agents are effective in the treatment [39].
8. PASH syndrome
The clinical trial of pyoderma gangrenosum, acne conglobata, and hidradenitis suppurativa 
was described as PASH syndrome by Braun-Falco et al. in 2012. PASH syndrome clinically 
resembles pyoderma gangrenosum, acne conglobata, and pyogenic arthritis (PAPA) syn-
drome, but arthritis is not observed [40].
The molecular basis of PASH syndrome is not known very well. It is accepted as autoin-
flammatory disease. PAPA (pyogenic arthritis, pyoderma gangrenosum, and acne), PAPASH 
(pyogenic arthritis and PASH), and PASH (pyoderma gangrenosum, acne conglobata and 
hidradenitis suppurativa) syndromes clinically have similar components. The absence of 
pathogenic mutations in the PSTPIP1 gene may be used for distinguishing this syndrome 
from other AIDs [41, 42]. Although a genetic mutation was not discovered clearly in PASH 
syndrome, in some case series, NCSTN gene, NOD (nucleotide-binding oligomerization 
domain) genes, the immunoproteasome, and MEFV mutations were reported in PASH syn-
drome [41, 42].
Systemic corticosteroids, traditional antineutrophilic agents (dapsone and colchicine), and 
metformin may be tried at first but standard therapy options for autoinflammatory diseases 
are not usually enough to treat patients with PAPA and PASH syndrome whereas anti-TNF 
therapies and anti-IL-1 therapy are promising new treatment options for drug resistant 
cases [43].
Author details
Nazan Emiroglu
Address all correspondence to: dr.nazanyilmaz@hotmail.com
Department of Dermatology, Bezmialem Vakif University, Istanbul, Turkey
References
[1] Cerman AA, Aktaş E, Altunay İK, Arıcı JE, Tulunay A, Ozturk FY. Dietary glycemic fac-
tors, insulin resistance, and adiponectin levels in acne vulgaris. J Am Acad Dermatol. 
2016; 75(1):155–62. Doi: 10.1016/j.jaad.2016.02.1220.
[2] Araviiskaia E, Dréno B. The role of topical dermocosmetics in acne vulgaris. J Eur Acad 
Dermatol Venereol. 2016; 30(6):926–35. Doi: 10.1111/jdv.13579
Acne-Associated Syndromes
http://dx.doi.org/10.5772/65635
169
[3] Pace JL. Acne—a potential skin marker of internal disease. Clin Dermatol. 2015; 
33(5):572–8. Doi: 10.1016/j.clindermatol.2015.05.010.
[4] Chen W, Obermayer-Pietsch B, Hong JB, Melnik BC, Yamasaki O, Dessinioti C et al. 
Acne-associated syndromes: models for better understanding of acne pathogenesis. 
J Eur Acad Dermatol Venereol. 2011; 25(6):637–46. Doi: 10.1111/j.1468-3083.2010.03937.x.
[5] Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007; 
370(9588):685–97. Doi: 10.1016/S0140-6736(07)61345-2.
[6] Dastur Adi E, Tank P D. Irving Stein, Michael Leventhal and a slice of endocrine history. 
J Obstet Gynecol India. 2010; 60(2):121–122. Doi: 10.1007/s13224-010-0016-1.
[7] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 
consensus on diagnostic criteria and long-term health risks related to polycystic ovary 
syndrome. Fertil Steril. 2004; 81(1):19–25. Doi:10.1016/j.fertnstert.2003.10.004
[8] Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, 
Futterweit W, et al. The androgen excess and PCOS society criteria for the polycystic 
ovary syndrome: the complete task force report. Fertil Steril. 2009; 91(2):456–88. Doi: 
10.1016/j.fertnstert.2008.06.035.
[9] Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R. Diagnosis 
and treatment of polycystic ovary syndrome: an endocrine society clinical practice 
guideline. J Clin Endocrinol Metab. 2013; 98(12):4565–92. Doi: 10.1210/jc.2013-2350.
[10] Housman E, Reynolds RV. Polycystic ovary syndrome: a review for dermatologists: Part 
I. Diagnosis and manifestations. J Am Acad Dermatol. 2014; 71(5):847. Doi: 10.1016/j.
jaad.2014.05.007.
[11] Schmidt TH, Shinkai K. Evidence-based approach to cutaneous hyperandrogenism in 
women. J Am Acad Dermatol. 2015; 73(4):672–90. Doi: 10.1016/j.jaad.2015.05.026.
[12] Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin 
Dermatol. 2007; 8(4):201–219. Doi: 10.2165/00128071-200708040-00003.
[13] Schmidt TH, Khanijow K, Cedars MI, Huddleston H, Pasch L, Wang ET, et al. Findings 
and systemic associations in women with polycystic ovary syndrome. JAMA Dermatol. 
2016; 152(4):391–8. Doi: 10.1001/jamadermatol.2015.4498.
[14] Buzney E, Sheu J, Buzney C, Reynolds RV. Polycystic ovary syndrome: a review for 
dermatologists: Part II. Treatment. J Am Acad Dermatol. 2014; 71(5):859. Doi: 10.1016/j.
jaad.2014.05.009
[15] Dédjan AH, Chadli A, El Aziz S, Farouqi A. Hyperandrogenism-Insulin resistance-acan-
thosis nigricans syndrome. Case Rep Endocrinol. 2015; 193097. Doi: 10.1155/2015/193097.
[16] Omar HA, Logsdon S, Richards J. Clinical profiles, occurrence, and management of ado-
lescent patients with HAIR-AN syndrome. Sci World J. 2004 Jul 8; 4:507–11. Doi: 10.1100/
tsw.2004.106
Acne and Acneiform Eruptions170
[17] Elmer KB, George RM. HAIR-AN syndrome: a multisystem challenge. Am Fam 
Physician. 2001 Jun 15; 63(12):2385–90.
[18] Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, 
et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by 
the androgen excess and polycystic ovary syndrome society. Hum Reprod Update. 2012; 
18(2):146–70. Doi: 10.1093/humupd/dmr042.
[19] Chang RJ, Katz SE. Diagnosis of polycystic ovary syndrome. Endocrinol Metab Clin 
North Am. 1999; 28(2):397–408, vii.
[20] Zemtsov A, Wilson L. Successful treatment of hirsutism in HAIR-AN syndrome using 
flutamide, spironolactone, and birth control therapy. Arch Dermatol. 1997; 133(4):431–3. 
Doi:10.1001/archderm.1997.03890400023003.
[21] Dalamaga M, Papadavid E, Basios G, Vaggopoulos V, Rigopoulos D, Kassanos D, et al. 
Ovarian SAHA syndrome is associated with a more insulin-resistant profile and repre-
sents an independent risk factor for glucose abnormalities in women with polycystic 
ovary syndrome: a prospective controlled study. J Am Acad Dermatol. 2013; 69(6):922–
30. Doi: 10.1016/j.jaad.2013.09.014.
[22] Lowenstein EJ. Diagnosis and management of the dermatologic manifesta-
tions of the polycystic ovary syndrome. Dermatol Ther. 2006; 19(4):210–23. 
Doi:10.1111/j.1529-8019.2006.00077.x.
[23] DeGiovanni CV, Jong C, Woollons A. What syndrome is this? Apert syndrome. Pediatr 
Dermatol. 2007; 24(2):186–8. Doi:10.1111/j.1525-1470.2007.00372.x.
[24] Ko JM. Genetic syndromes associated with craniosynostosis. J Korean Neurosurg Soc. 
2016; 59(3):187–91. Doi:10.3340/jkns.2016.59.3.187.
[25] Dolenc-Voljc M, Finzgar-Perme M. Successful isotretinoin treatment of acne in a patient 
with Apert syndrome. Acta Derm Venereol. 2008; 88(5):534–5. Doi: 10.2340/00015555-0501.
[26] Benjamin LT, Trowers AB, Schachner LA. Successful acne management in Apert syn-
drome twins. Pediatr Dermatol. 2005; 22(6):561–5. Doi: 10.1111/j.1525-1470.2005.00141.x.
[27] Cohen MM Jr., Kreiborg S. Cutaneous manifestations of Apert syndrome. Am J Med 
Genet. 1995; 31; 58(1):94–6. Doi: 10.1002/ajmg.1320580119.
[28] Melnik BC. Role of FGFR2-signaling in the pathogenesis of acne. Dermatoendocrinol. 
2009; 1(3):141–56.
[29] Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Acne-pustulosis-
hyperostosis-osteitis syndrome. Results of a national survey. 85 cases. Rev Rhum Mal 
Osteoartic. 1987; 54(3):187–96.
[30] Zhao Z, Li Y, Li Y, Zhao H, Li H. Synovitis, acne, pustulosis, hyperostosis and osteitis 
(SAPHO) syndrome with review of the relevant published work. J Dermatol. 2011 Feb; 
38(2):155–9. Doi: 10.1111/j.1346-8138.2010.00931.x.
Acne-Associated Syndromes
http://dx.doi.org/10.5772/65635
171
[31] Yamamoto T. Pustulotic arthro-osteitis associated with palmoplantar pustulosis. J 
Dermatol. 2013; 40(11):857–63. Doi: 10.1111/1346-8138.12272.
[32] Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, Grootenboer-Mignot S, Ruimy 
R, Meyer O, et al. Characterization of the immune response in the synovitis, acne, 
pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology (Oxford). 2008; 
47(8):1160–7. Doi: 10.1093/rheumatology/ken185.
[33] Firinu D, Garcia-Larsen V, Manconi PE, Del Giacco SR. SAPHO syndrome: current 
developments and approaches to clinical treatment. Curr Rheumatol Rep. 2016; 18(6):35. 
Doi: 10.1007/s11926-016-0583-y.
[34] Marzano AV, Borghi A, Meroni PL, Cugno M. Pyoderma gangrenosum and its syn-
dromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016; 23. Doi: 
10.1111/bjd.14691.
[35] Firinu D, Murgia G, Lorrai MM, Barca MP, Peralta MM, Manconi PE, et al. Biological 
treatments for SAPHO syndrome: an update. inflamm allergy drug targets. 2014; 
13(3):199–205. Doi: 10.2174/1871528113666140520100402
[36] Wendling D, Prati C, Aubin F. Anakinra treatment of SAPHO syndrome: short-
term results of an open study. Ann Rheum Dis. 2012; 71(6):1098–100. Doi: 10.1136/
annrheumdis-2011-200743
[37] Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT. A new auto-
somal dominant disorder of pyogenic sterile arthritis, pyoderma gangreno-
sum, and acne: PAPA syndrome. Mayo Clin Proc. 1997;72(7):611–5. Doi: 10.1016/
S0025-6196(11)63565-9
[38] Smith EJ, Allantaz F, Bennett L, Zhang D, Gao X, Wood G, et al. Clinical, molecular, and 
genetic characteristics of PAPA syndrome: a review. Curr Genomics. 2010;11(7):519–27. 
Doi: 10.2174/138920210793175921.
[39] Geusau A1, Mothes-Luksch N, Nahavandi H, Pickl WF, Wise CA, Pourpak Z, et al. 
Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syn-
drome responding to canakinumab treatment. JAMA Dermatol. 2013; 149(2):209–15. 
Doi: 10.1001/2013.jamadermatol.717.
[40] Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, 
and suppurative hidradenitis (PASH)—a new autoinflammatory syndrome dis-
tinct from PAPA syndrome. J Am Acad Dermatol. 2012;66(3):409–15. Doi: 10.1016/j.
jaad.2010.12.025.
[41] Marzano AV, Trevisan V, Gattorno M, Ceccherini I, De Simone C, Crosti C. Pyogenic 
arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new 
autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. 
JAMA Dermatol. 2013;149(6):762–4. Doi: 10.1001/jamadermatol.2013.2907.
Acne and Acneiform Eruptions172
[42] Calderón-Castrat X, Bancalari-Diaz D, Román-Curto C, Romo-Melgar A, Amorós-Cerdán 
D2, A Alcaraz-Mas L2, et al. PSTPIP1 Gene mutation in a pyoderma gangrenosum, acne 
and suppurative hidradenitis (PASH) Syndrome. Br J Dermatol. 2016; 175(1):194–8. Doi: 
10.1111/bjd.14383.
[43] Staub J, Pfannschmidt N, Strohal R, Braun-Falco M, Lohse P, Goerdt S, et al. Successful 
treatment of PASH syndrome with infliximab, cyclosporine and dapsone. J Eur Acad 
Dermatol Venereol. 2015; 29(11):2243–7. Doi: 10.1111/jdv.12765
Acne-Associated Syndromes
http://dx.doi.org/10.5772/65635
173

